New vaginal transmucosal drug delivery system based on BSA-H loaded with CCL7 (human) recombinant protein for stem cell therapy chemotaxis in muscle regeneration

• Grant number: 18/25410-0
• Support Opportunities: Scholarships abroad - Research Internship - Post-doctor
• Start date: April 29, 2019
• End date: October 28, 2019
• Field of knowledge: Health Sciences - Medicine - Maternal and Child Health
• Principal Investigator: Marilza Vieira Cunha Rudge
• Grantee: Juliana Ferreira Floriano
• Supervisor: Adonis Khezaee Hijaz
• Host Institution: Faculdade de Medicina (FMB). Universidade Estadual Paulista (UNESP). Campus de Botucatu. Botucatu , SP, Brazil
• Institution abroad: Case Western Reserve University, United States
• Associated to the scholarship: 17/21783-4 - Gestational triad cohort: hyperglycemia, urinary incontinence and clinical, molecular and omic profile of hyperglycemic myopathy in predicting incontinence and muscle dysfunction and translational research with biodevice for muscle regeneration in rats, BP.PD

Abstract

Gestational diabetes promotes deleterious effects on the muscles of the pelvic floor and rectus abdominis muscle, leading to urinary incontinence in these women up to two years postpartum due to gestational diabetic myopathy, a condition characterized by various muscle changes and atrophy. The Diamater research group, through the thematic project Fapesp 2016 / 01743-5, intensified its efforts in the understanding and treatment of this pathology. Currently, the treatment of gestational diabetic myopathy and urinary incontinence is ineffective, raising public health costs and decreasing the quality of life of women. Therefore, it is necessary to develop new research in this area in order to develop new, more effective and safe therapeutic approaches for diabetic gestational myopathy and urinary incontinence. Recently, new approaches to this treatment are based on regenerative medicine and stem cell therapy, through the sustained release of chemokines, either systemically or locally. The release of chemotactic chemokines proved to be a proposal with great chances of success for effective regeneration. For this reason, this research project aims to develop and patent a new, unprecedented Transmucous Vaginal Drug Delivery System (VTMDS), with sustained release of chemotactic chemokines (CCL7), based on heparin crosslinked with bovine serum albumin (BSA-H), as a new approach to regeneration muscle and UI treatment in preclinical studies. But with great translational potential, allowing a possibly more effective and safer therapy. The development of this new treatment platform makes the way for the treatment of other pathologies in the future. (AU)